These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6980747)

  • 1. Immune complexes in leprosy patients from an endemic and a nonendemic area and a longitudinal study of the relationship between complement breakdown products and the clinical activity of erythema nodosum leprosum.
    Valentijn RM; Faber WR; Lai A Fat RF; Chan Pin Jie JC; Daha MR; van Es LA
    Clin Immunol Immunopathol; 1982 Feb; 22(2):194-202. PubMed ID: 6980747
    [No Abstract]   [Full Text] [Related]  

  • 2. An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL).
    Saha K; Chakraborty AK; Sharma V; Sehgal VN
    Lepr Rev; 1982 Dec; 53(4):253-60. PubMed ID: 6984124
    [No Abstract]   [Full Text] [Related]  

  • 3. The immunopathology of erythema nodosum leprosum: the role of extravascular complexes.
    Ridley MJ; Ridley DS
    Lepr Rev; 1983 Jun; 54(2):95-107. PubMed ID: 6350778
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune complexes and complement hypercatabolism in patients with leprosy.
    Bjorvatn B; Barnetson RS; Kronvall G; Zubler RH; Lambert PH
    Clin Exp Immunol; 1976 Dec; 26(3):388-96. PubMed ID: 1009681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum immune complexes in erythema nodosum leprosum reactions of leprosy.
    Rao TD; Rao PR
    Indian J Lepr; 1988 Apr; 60(2):189-95. PubMed ID: 3142953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of anti-reactional drugs on complement components in the type II, erythema nodosum leprosum, reaction.
    Sehgal VN; Sharma V; Sharma VK
    Br J Dermatol; 1988 Aug; 119(2):255-8. PubMed ID: 3166944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive evaluation of complement components in the course of type I (Lepra) and type II (ENL) reactions.
    Sehgal VN; Sharma V; Sharma VK
    Int J Dermatol; 1989; 28(1):32-5. PubMed ID: 2783924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement determinations in the synovial fluid and serum of a patient with Erythema nodosum leprosum.
    Louie JS; Glovsky M
    Int J Lepr Other Mycobact Dis; 1975; 43(3):252-5. PubMed ID: 1240873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load.
    Saha K; Sharma V; Chakrabarty AK; Sehgal VN
    Scand J Immunol; 1983 Jan; 17(1):37-43. PubMed ID: 6342123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythema nodosum leprosum (ENL) in histoid leprosy.
    Sehgal VN; Gautam RK; Srivastava G; Koranne RV; Beohar PC
    Indian J Lepr; 1985; 57(2):346-9. PubMed ID: 4078360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune complexes in diabetes mellitus: studies of complement utilisation and tissue deposition.
    Charlesworth JA; Campbell LV; Catanzaro R; Pussell BA; Pasterfield GV; Peake P
    J Clin Lab Immunol; 1982 Sep; 8(3):163-8. PubMed ID: 6752415
    [No Abstract]   [Full Text] [Related]  

  • 12. Lucio's phenomenon: an immune complex deposition syndrome in lepromatous leprosy.
    Quismorio FP; Rea T; Chandor S; Levan N; Friou GJ
    Clin Immunol Immunopathol; 1978 Feb; 9(2):184-93. PubMed ID: 618690
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunohistological studies of skin biopsies from patients with lepromatous leprosy.
    Mshana RN; Humber DP; Belehu A; Harboe M
    J Clin Immunol; 1983 Jan; 3(1):22-9. PubMed ID: 6338025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyethylene glycol precipitates in serum during and after erythema nodosum leprosum--study of their composition and anticomplementary activity.
    Saha K; Chakrabarty AK; Sharma VK; Sehgal VN
    Int J Lepr Other Mycobact Dis; 1984 Mar; 52(1):44-8. PubMed ID: 6538557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of complement by circulating immune complexes isolated from leprosy patients.
    Tyagi P; Ramanathan VD; Girdhar BK; Katoch K; Bhatia AS; Sengupta U
    Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):31-8. PubMed ID: 2319186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgM anti-phenolic glycolipid I and IgG anti-10-kDa heat shock protein antibodies in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts.
    Rojas RE; Demichelis SO; Sarno EN; Segal-Eiras A
    FEMS Immunol Med Microbiol; 1997 Sep; 19(1):65-74. PubMed ID: 9322070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum complement (C3) in leprosy.
    Shwe T
    Lepr Rev; 1971 Dec; 42(4):268-72. PubMed ID: 5005221
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence for circulating immune complexes in lepromatous leprosy.
    Moran CJ; Ryder G; Turk JL; Waters MF
    Lancet; 1972 Sep; 2(7777):572-3. PubMed ID: 4115742
    [No Abstract]   [Full Text] [Related]  

  • 19. Activation of complement (C3) in patients with leprosy.
    Shwe T; Petty RE
    Lepr Rev; 1971 Dec; 42(4):277-81. PubMed ID: 5154346
    [No Abstract]   [Full Text] [Related]  

  • 20. Complement activation and C1q binding activity in haemodialysis.
    Dodd NJ; Vergani D; Turney JH; Parsons V; Weston MJ
    Proc Eur Dial Transplant Assoc; 1981; 18():300-4. PubMed ID: 6977138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.